An
Expanded Discussion of The Synergistic Effects Within My Theoretical Protocol
By
James
E. Bare, D.C.
September
2026
This protocol enlists multiple mechanisms that are
selectively lethal only to cancer cells.
Unlike ionizing radiation, chemotherapy
and surgery, this protocol does not detrimentally affect healthy cells and
organs of the body. The protocol
is non toxic ! A person using this protocol will not
suffer the damaging effects common to that of surgery, chemotherapy,
and radiation. All to often , the physical state
following treatment with conventional therapies is somewhere close to
death. Those utilizing this protocol successfully should only have to recover
from the effects of the cancer on their bodies. Not the treatment !
There is now a whole library of published and presented
papers on the effects of Oscillating Electrical fields both pulsed and non
pulsed, on many different cancer types. As
such, the utilized frequency device in this protocol should be capable of
producing oscillating Electrical fields.
These fields can be presented to the body via direct contact
electrodes, or via the use of a gas plasma antenna driven by RF,
or oscillating high voltage electricity . TT fields are oscillating E fields in the 80,000hz to
400,000hz range.
Some of the effects on cancer cells within this protocol
overlap - but some are unique to each of the protocol constituents. In total,
there are in total over 40 different ways that cancer is inhibited, prevented
from metastasis, and ultimately destroyed
by the protocol. 40 + different ways, via 6 different mechanisms , are
being simultaneously applied to cancer cells with this protocol !
Listed below are 6 major mechanisms labeled A through F, that compose my theoretical protocol .
Some reminders:
Protocols exist for Ivermectin/Fenbenzadole or for
Ivermectin/ Mebendazole
. It will be wise to choose a protocol from a well respected physicians
web site or, ideally seek out a physician local to you that is using this
protocol. Use only two of the three anthelmentics mentioned , and not include
the third anthelmentic.
Anthelmentics need to be taken with or after a fatty meal. They
are fat soluble and need bile to be absorbed from one's
intestines. Thus they should not be taken on an empty stomach, a
meal with no fat in it.
One needs to ingest 15 to 40 grams of fat prior to each
dose.
Fats
( as oils) that can be used :
Olive
Oil, Butter, Coconut Oil, Avocado Oil, Nuts and Nut Butters , Vit E Oil, CBD
Oil, and Eggs.
Quercetin : One
must use Quercetin Phytosome with Bromelain for optimal absorption. Otherwise
only about 17% of the dose is absorbed. 500mg to 1000 mg/day is typical dose
and that total is suggested to be taken in smaller multiple doses.
Do not use other types of quercetin due to poor absorption.
Comment
on the informational text that follows:
The
information below, is essentially 100 % Copied from
search engine queries ( Brave) and is not original to my authorship. It
all should be considered as a quote.
A. Immune System Activation:
1. Ivermectin allows the
immune system to recognize cancer cells
Research
indicates that ivermectin can activate the immune system
against cancer by inducing immunogenic cell death (ICD) and
modulating the tumor microenvironment
https://www.nature.com/articles/s41523-021-00229-5
2. Mebendazole activates
the immune system primarily by inducing a pro-inflammatory M1
phenotype in monocytes and macrophages, which enhances T-cell
activation and tumor cell killing.
https://pmc.ncbi.nlm.nih.gov/articles/PMC6089388/
3. Fenbendazole enhances the immune systems ability to fight cancer through indirect means. It is reported to modulate the immune system against cancer through M1 polarization and the induction of ferroptosis, which enhances immune-mediated tumor cell death. Research indicates it may act as an immune checkpoint inhibitor and reduce PD-L1 expression, thereby potentially counteracting immune suppression within the tumor microenvironment.
4. Quercetin activates
the immune system against cancer cells by modulating the tumor
microenvironment (TME) and enhancing the activity of key immune
effectors. It promotes the infiltration and cytotoxic function
of CD8+ T cells, natural killer (NK) cells, and γδ
T cells while simultaneously inhibiting immunosuppressive cells like
regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs)ve
oxygen species, all of which are mechanistically linked to ferroptotic cell
death.
https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1483459/full
5. Tumor Treating Fields (TTFields) activate
the immune system primarily by inducing immunogenic cell death (ICD) in
cancer cells, which releases damage-associated molecular patterns (DAMPs)
like calreticulin, ATP, and HMGB1
https://link.springer.com/article/10.1007/s00262-020-02534-7
B.
Tumor Suppressor Gene Activation
1. Fenbendazole promotes TP53 activation and selective cancer cell inhibition
https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1483459/full
2.
Ivermectin upregulates
the expression of the p53 tumor suppressor gene
3. Mebendazole
A 2026 study published
in PLOS ONE found that mebendazole significantly
upregulates the tumor suppressor gene RASSF1A, causing its
expression to increase by more than 200-fold in endothelial
cells. The drug also strongly induced the tumor suppressor WFDC10A,
which rose by more than 40-fold in MDA-MB-231 breast cancer
cells. Additionally, research on diffuse midline glioma and lung
cancer models indicates that mebendazole upregulates the tumor
suppressors p53 and p21.
https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0345701
4. Quercetin
activates the expression of P53, PTEN, BAX,
FOXO1 ,FOXO3, and Klotho, TP73, CYLD, CBX7
https://pmc.ncbi.nlm.nih.gov/articles/PMC7957552/
5. Tumor Treating Fields (TTFields) upregulate
key tumor suppressor genes, including TP53, CDKN2A,
and CDKN1A (p21), while simultaneously downregulating
oncogenes such as MYC and E2F.
https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1274587/full
C. Metastasis Inhibition:
2. Mebendazole has
demonstrated significant efficacy in inhibiting cancer metastasis across
multiple preclinical models, including breast, thyroid, pancreatic,
and lung cancers. The drug primarily works
by disrupting tubulin polymerization, which leads to mitotic
arrest and apoptosis, while also suppressing key signaling pathways involved
in cell migration and invasion.
https://pmc.ncbi.nlm.nih.gov/articles/PMC9798635/
3.
Quercetin
significantly inhibits cancer metastasis across
multiple malignancies, including breast, prostate, lung, colon, and gastric
cancers, by suppressing the epithelial-mesenchymal transition (EMT) and
reducing the secretion of matrix metalloproteinases (MMPs) and vascular
endothelial growth factor (VEGF)
https://www.sciencedirect.com/science/article/pii/S0753332219352266
4. Fenbendazole
Recent studies confirm it suppresses metastasis by downregulating
MMP2 and MMP9 expression and inhibiting the ROCK1 marker,
while also reducing glucose uptake to starve tumors of the
energy needed for spread.
https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1596694/full
5.Tumor Treating Fields (TTFields) have been shown to inhibit metastasis. Preclinical
studies in mice and rabbits demonstrated that TTFields significantly
reduce the number and size of lung metastases from solid tumors like
melanoma and VX-2 carcinoma
https://pmc.ncbi.nlm.nih.gov/articles/PMC2776150/
D.
Stem Cell Inhibition -
stem
cells are responsible for the development of therapy resistance, metastatic
spread, and cancer reoccurrence with treatment failure.
1. Fenbendazole exhibits preclinical
antitumor activity by dual-targeting both bulk cancer cells and cancer
stem cells (CSCs), which are primarily responsible for therapy resistance
and metastatic spread.
https://www.mdpi.com/1420-3049/30/11/2377
2. Ivermectin exhibits
significant anticancer activity by targeting cancer stem cells (CSCs) and
inhibiting metastasis through multiple molecular mechanisms.
3. Mebendazole prevents
distant organ metastases and reduces primary tumor growth in preclinical
models of triple-negative breast cancer (TNBC) and thyroid
cancer by targeting cancer stem cells and disrupting
metastatic pathways.
https://pmc.ncbi.nlm.nih.gov/articles/PMC9798635/
4. Quercetin inhibits
cancer stem cell (CSC) metastasis primarily by suppressing the
Epithelial-Mesenchymal Transition (EMT) and downregulating key signaling
pathways.
https://pubmed.ncbi.nlm.nih.gov/29353288/
5. Tumor Treating Fields (TTFields) inhibit
the proliferation, survival, and migration of mesenchymal stromal
cells (MSCs) and cancer stem-like cells, while their
effect on normal neural stem cells is context-dependent.
https://pubmed.ncbi.nlm.nih.gov/38900237/
E.
Tumor Suppressor Gene Activation
1.
Mebendazole activates or upregulates
several tumor suppressor genes, with effects varying by cancer type and cell
line. Key activated tumor suppressors include:
·
RASSF1A: Strongly induced
(>200-fold) in endothelial cells and upregulated in HEPG2 and HT29 cancer
cells.
·
WFDC10A: Dramatically elevated
(>40-fold) in MDA-MB-231 breast
cancer cells.
·
METTL7A: Displays heterogeneous
regulation with enrichment in endothelial cells.
·
CDKN1A: Upregulated in gastric
cancer cells
(AGP-01).
Additionally,
mebendazole induces a tumor-suppressive M1 phenotype in
monocytes and macrophages, enhancing T-cell activation and tumor cell
killing.
The
clearest evidence comes from the 2026 PLOS ONE study, which
tested EA.hy926 (a normal human umbilical vein endothelial
cell line) alongside cancer lines:
·
RASSF1A was upregulated >200-fold in
EA.hy926 endothelial cells (p < 0.01) — the strongest induction observed
in any cell type tested, even exceeding the response in
cancer lines like HEPG2 and HT29. The
authors note this suggests mebendazole can "bring back or boost tumor
suppressor gene function especially in endothelial cells," potentially
normalizing tumor vasculature.
·
METTL7A is intrinsically enriched
in endothelial cells at basal levels, with heterogeneous drug-dependent
changes across tumor lines.
However,
this gene-level effect sits in a broader context of selective toxicity:
across multiple studies, mebendazole causes ~10× less cytotoxicity in normal
cells (HUVECs, WI-38 fibroblasts, normal PBMCs) than in cancer cells at
equivalent concentrations. So while tumor suppressor transcription is
measurably induced in non-cancer cells, the downstream functional consequences
(growth arrest, apoptosis) are largely absent — the drug's phenotypic
effects remain predominantly tumor-selective.
2. Ivermectin
·
p53: Ivermectin upregulates p53 expression, enhancing its
tumor-suppressive functions.
·
p21: By repressing WNT-TCF transcriptional responses, ivermectin
increases p21 levels, thereby inhibiting cell cycle progression.
·
APC: The drug promotes the repressor of WNT signaling, FILIP1L,
which helps limit the translocation of β-catenin and supports the
function of the APC tumor suppressor in limiting metastatic
events.
3. Fenbendazole
Research
indicates that fenbendazole increases the stability and transcriptional
activity of wild-type p53 by downregulating its negative regulators,
specifically Mdm2 and MdmX. This
activation triggers downstream effects such as:
·
Cell Cycle Arrest: Upregulation of p21,
which halts cell division at the G1/S and G2/M checkpoints.
·
Apoptosis Induction: Activation of
pro-apoptotic genes like TIGAR and SCO2.
·
Metabolic Disruption: Inhibition of glucose
uptake and glycolysis via HK2 (Hexokinase 2) downregulation,
leading to pyroptosis in certain cancer types like breast cancer.
The overall
finding across multiple studies is that fenbendazole is selectively
toxic to cancer cells while largely sparing normal cells.
4. Quercetin:
·
p53 and p21: Frequently upregulated in
prostate, cervical, colon, and breast cancers to induce cell cycle arrest and
apoptosis.
·
PTEN: Activated in colon and prostate cancers to inhibit the
PI3K/Akt survival pathway.
·
FOXO1: Upregulated in lymphoma and metastatic models to promote
apoptosis and inhibit NF-κB activity.
·
Klotho and SIRT-6: Stimulated in colon cancer
cells to inhibit insulin/IGF1 and Wnt signaling pathways.
·
APC, TGFβR2, Rb, p57Kip2, TSC-2: Induced in prostate cancer
cells to suppress colony formation and aggressive potential.
·
CBX7 and CYLD: Upregulated in bone cancer
models to inhibit proliferation and enhance apoptosis.
Research
indicates that quercetin exhibits cancer
cell-specific toxicity, meaning it induces cytotoxicity in malignant cells
while having limited or no effect on normal, non-transformed cell.
5. TT Fields
Tumor Treating Fields (TTFields) activate tumor suppressor pathways by modulating
the cancer cell transcriptome, specifically leading to the upregulation
of tumor suppressor genes such as TP53 and CDKN2A.
·
This
transcriptional shift occurs alongside the downregulation of oncogenes like MYC and E2F,
creating a cellular environment that inhibits proliferation.
·
The
activation of these suppressors contributes to cell cycle arrest and
the induction of immunogenic cell death (ICD), which helps convert
immunologically "cold" tumors into "hot" ones responsive
to immune clearance.
F.
Onco Gene Inhibition: Oncogenes
promote cancer growth and spread. There is evidence that it is possible to
inhibit/suppress ( down regulate) the activities of these genes using the
components of this theoretical protocol.
1.
Ivermectin suppresses
oncogenes by modulating multiple signaling pathways, including Wnt/β-catenin, PI3K/Akt/mTOR,
and STAT3, which leads to the inhibition of cancer cell
proliferation and the induction of apoptosis.
·
HSP27
Inhibition: Ivermectin inhibits HSP27, which reduces the
nuclear transport and activity of androgen receptor (AR) variants and EGFR, thereby potentiating
the efficacy of targeted therapies in prostate and lung cancer models.
·
YAP1
Suppression:
The drug inhibits the proliferation of gastric cancer cells by blocking the
activity of YAP1, an oncogene critical
for tumorigenesis.
·
Stemness
Markers: Ivermectin downregulates
stemness genes such as NANOG, OCT-4, and SOX-2, effectively
suppressing cancer stem-like cells in breast cancer and hepatocellular
carcinoma.
·
PAK1
Degradation:
It induces the degradation of PAK1 via the proteasome-dependent
pathway, inhibiting migration and invasion in esophageal squamous cell
carcinoma.
·
MDR
Reversal: Ivermectin reverses multidrug
resistance by inhibiting the EGFR/ERK/Akt/NF-κB pathway, which
downregulates the expression of P-gp (P-glycoprotein) in resistant
tumor cells.
2.
Mebendazole suppresses
oncogenes and reprograms oncogenic networks by downregulating pro-cancer genes
while activating tumor suppressors. Preclinical studies demonstrate that mebendazole
significantly downregulates ENOX2 (an oncogene promoting
cancer growth) and MMP2 (which drives invasion and
metastasis) across various cancer cell lines, including liver, leukemia, and
breast cancer.
Simultaneously, the drug
activates key tumor suppressors, including RASSF1A (increasing
expression more than 200-fold in endothelial cells) and WFDC10A (increasing
more than 40-fold in breast cancer cells). This dual mechanism
effectively turns down cancer-promoting signals while turning up
cancer-suppressing pathways.
Additional oncogenic
suppression mechanisms include:
·
Downregulation
of c-Myc:
Reduced protein expression and mRNA levels of this proto-oncogene.
·
Inhibition
of RAN GTPase:
Disruption of AKT and Ran signaling pathways to halt proliferation in
triple-negative breast and lung cancer.
·
Suppression
of PI3K/Akt and STAT3:
Inhibition of these signaling axes reduces metastatic potential in thyroid and
pancreatic cancer models.
·
Blockade
of Hedgehog and Wnt Pathways: Interference with signaling crucial for cancer stem
cell self-renewal.
3.
Fenbendazole suppresses
oncogenic signaling pathways, including Notch1, PI3K/AKT,
and NF-κB, which are critical for cancer cell survival and
proliferation. Additionally, it inhibits the expression of specific
oncogenes and proteins such as HER2, Ki-67, and proliferating
cell nuclear antigen (PCNA) to reduce tumor growth. In
KRAS-mutant lung cancer, fenbendazole specifically targets and
suppresses KRAS-mutant cells, offering a potential therapeutic
avenue for this resistant cancer type.
4.
Quercetin suppresses oncogenes by directly down-regulating
the expression of various genes that control cell growth and oncogenesis, such
as AKT-1 and CDK2, while reciprocally
up-regulating tumor suppressor genes like p53. This
dual mechanism inhibits the cell cycle (specifically at the G1 and G2/M phases)
and promotes apoptosis in cancer cells, particularly in aggressive prostate,
breast, and lung cancer cell lines.
·
Prostate
Cancer:
Quercetin significantly down-regulates oncogenes including AKT-1 and CDK2 in
aggressive PC-3 and DU-145 cell lines, while up-regulating tumor suppressors
like p53 and TSC-1/2.
·
Breast
Cancer:
It reduces oncogenic potential by suppressing Twist protein
and down-regulating Cyclin D1, thereby inhibiting proliferation in
MCF-7 cells.
·
General
Mechanisms:
Quercetin modulates key signaling pathways such as PI3K/Akt/mTOR and MAPK/ERK,
reducing the expression of pro-oncogenic proteins like Ras and STAT phosphorylation.
·
Epigenetic
Modulation:
It influences the expression of microRNAs (miRNAs), inhibiting
oncomiRs (e.g., miR-21) and enhancing tumor suppressor miRNAs
(e.g., miR-34a and Let-7 family) to suppress
oncogenic pathways
5.
TTFields significantly downregulate key oncogenes, including MYC and E2F,
while upregulating tumor suppressor genes like TP53 and CDKN2A. This
transcriptional reprogramming suppresses cell cycle, growth, and proliferation
pathways, contributing to the inhibition of tumor cell division and
survival.
Specific molecular
effects include:
·
Downregulation
of ONCOGENES:
Expression of MYC and E2F is reduced,
leading to decreased proliferative signaling.
·
Suppression
of DNA Repair:
The Fanconi Anemia-BRCA pathway is downregulated, impairing
the repair of DNA double-strand breaks and increasing replication
stress.
·
Inhibition
of Growth Pathways:
Signaling pathways such as PI3K-AKT and MAPK are
suppressed, while genes involved in epithelial-to-mesenchymal transition (EMT)
like Tenascin C (TNC) and VEGFA are
downregulated.
·
Metabolic
Disruption:
Expression of PKM2 is reduced, shifting cancer cell
metabolism from glycolysis to oxidative phosphorylation.